Non-Cytokine Protein Profile of the Mesenchymal Stem Cell Secretome That Regulates the Androgen Production Pathway.
Hang-Soo ParkRishi Man ChughMelissa R PergandeEsra CetinHiba SibliniSahar EsfandyariStephanie M ColognaAyman Al-HendyPublished in: International journal of molecular sciences (2022)
Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder in reproductive-aged women, and it typically involves elevated androgen levels. Recently, it has been reported that human bone marrow mesenchymal stem cells (hBM-MSCs) can regulate androgen synthesis pathways. However, the details of the mechanism are still unclear. hBM-MSC-derived secreted factors (the secretome) are promising sources of cell-based therapy as they consist of various types of proteins. It is thus important to know which proteins interact with disease-implicated biomolecules. This work aimed to investigate which secretome components contain the key factor that inhibits testosterone synthesis. In this study, we fractionated hBM-MSC-conditioned media into three fractions based on their molecular weights and found that, of the three fractions, one had the ability to inhibit the androgen-producing genes efficiently. We also analyzed the components of this fraction and established a protein profile of the hBM-MSC secretome, which was shown to inhibit androgen synthesis. Our study describes a set of protein components present in the hBM-MSC secretome that can be used therapeutically to treat PCOS by regulating androgen production for the first time.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- mesenchymal stem cells
- endothelial cells
- cell therapy
- amino acid
- binding protein
- bone marrow
- protein protein
- single cell
- small cell lung cancer
- gene expression
- stem cells
- drinking water
- type diabetes
- pregnant women
- skeletal muscle
- metabolic syndrome
- induced pluripotent stem cells
- genome wide identification